title: A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.
abstract: OBJECTIVE
  To evaluate the toxicity and clinical efficacy of liposomal encapsulated doxorubicin (DOX-SL) in the treatment of HIV-related Kaposi's sarcoma (KS).
  
  
  METHODS
  DOX-SL 20-40mg/m2 was administered by intravenous infusion over 30-60 minutes every two weeks. Toxicity was assessed in all patients and response assessed in patients who completed two or more cycles of therapy.
  
  
  RESULTS
  Twenty-five patients with KS were enrolled. Nine had received previous KS chemotherapy but only one prior anthracycline therapy. Eighteen patients had CD4 counts < 50/mm3. Eight had pulmonary and/or visceral KS. A total of 191 cycles were given, median 6, range 1-33. Twenty patients completed two or more cycles and were considered evaluable for efficacy. A defined response occurred in 11 patients, nine achieving a partial response and two a complete response. The median duration of response was 120 days and the median time to disease progression was 187 days. Acute toxicity was minimal, except in one patient who had generalised erythema, hypotension and diaphoresis within ten minutes of starting DOX-SL infusion. Grade 3 or 4 neutropenia occurred in 13.6 and 3.7% of cycles respectively. Neutropenic sepsis secondary to drug therapy was not reported. Alopecia and gastrointestinal symptoms were mild and infrequent. No cardiac toxicity was seen. Nine/25 patients developed HIV-associated illnesses while on study (three Pneumocystis carinii pneumonia, two systemic Cytomegalovirus infection, three cryptosporidiosis, one Mycobacterium avium intracellulare--(MAC) infection). Median survival in the evaluable patients was 219 days.
  
  
  CONCLUSIONS
  DOX-SL is an effective and well tolerated palliative therapy in AIDS-related KS.
authors.affiliation: National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Sydney.
authors.forename: M
authors.initials: M
authors.lastname: Newell
authors.forename: S
authors.initials: S
authors.lastname: Milliken
authors.forename: D
authors.initials: D
authors.lastname: Goldstein
authors.forename: C
authors.initials: C
authors.lastname: Lewis
authors.forename: M
authors.initials: M
authors.lastname: Boyle
authors.forename: G
authors.initials: G
authors.lastname: Dolan
authors.forename: S
authors.initials: S
authors.lastname: Ryan
authors.forename: D A
authors.initials: DA
authors.lastname: Cooper
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004337:Drug Carriers; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000821:virology; D016019:Survival Analysis